Attention Deficit Hyperactivity Disorder (ADHD): Clinical Trials

9 trials for Attention Deficit Hyperactivity Disorder (ADHD), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 withdrawn, 1 not yet recruiting, 1 recruiting. 9 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 49Completed 5, Withdrawn 2, Not yet recruiting 1, Recruiting 1

Follow Attention Deficit Hyperactivity Disorder (ADHD): new trials by email Literature Review of Attention Deficit Hyperactivity Disorder (ADHD) trials Research Report on Attention Deficit Hyperactivity Disorder (ADHD)

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
Adderall XR (mixed salts amphetamine), Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Autism
Phase 4RecruitingGagan Joshi1962026-02-012026-03-06
PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit /Hyperactivity Disorder
PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity. - Attention Deficit Hyperactivity Disorder (ADHD), Obesity (Body Mass Index &Amp;Amp;gt;30 kg/m2)
Phase 4Not yet recruitingUniversity Hospital, Tours302025-09-012025-08-13
A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.
methylphenidate HCl ERCT, Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder
Phase 4WithdrawnPfizer2018-10-312018-11-01
Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.
methylphenidate HCl ERCT - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 4WithdrawnPfizer2018-09-252018-11-01
Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting
AR11, Placebo - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 4CompletedArbor Pharmaceuticals, Inc.972013-12-012020-07-21
Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Lisdexamfetamine dimesylate - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 4CompletedShire3142011-07-072021-06-10
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 4CompletedXian-Janssen Pharmaceutical Ltd.1942009-12-012014-09-17
Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
Lisdexamfetamine - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 4CompletedMassachusetts General Hospital242008-04-012012-09-24
Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
Vyvanse (lisdexamfetamine dimesylate) - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 4CompletedShire3182007-06-282022-03-10

Narrower conditions

Attention Deficit Disorder with Hyperactivity (9)  ·  Autism Spectrum Disorder (1)  ·  Autistic Disorder (1)  ·  Obesity (1)  ·  Overweight (1)

Broader conditions

Attention Deficit and Disruptive Behavior Disorders (9)  ·  Mental Disorders (9)  ·  Neurodevelopmental Disorders (9)  ·  Body Weight (1)  ·  Child Development Disorders, Pervasive (1)  ·  Nutrition Disorders (1)  ·  Nutritional and Metabolic Diseases (1)  ·  Overnutrition (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)

Interventions

Lisdexamfetamine Dimesylate (3)  ·  Adiposity (1)  ·  Amphetamine (1)  ·  SLI381 (1)

Sponsors

Pfizer (2)  ·  Shire (2)  ·  Arbor Pharmaceuticals, Inc. (1)  ·  Gagan Joshi (1)  ·  Massachusetts General Hospital (1)  ·  University Hospital, Tours (1)  ·  Xian-Janssen Pharmaceutical Ltd. (1)

Countries

United States (4)  ·  Belgium (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Romania (1)  ·  Spain (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Gagan Joshi, MD (1)  ·  Laurence Downey, MD (1)  ·  Paul Hammerness, MD (1)

Results publications

PMID 20035583, PMID 21173426, PMID 21186969, PMID 26608976, PMID 28667569, PMID 29383572, PMID 29790103, PMID 30972657